8-K: ADC Therapeutics Q2 2026: Mixed Results Amidst FDA Concerns

ADC Therapeutics reported Q2 2026 financial results with $18.6M in net product revenue, but faces FDA concerns over LOTIS-5 trial data and announced a 17% workforce reduction.

Summary

• ADC Therapeutics reported Q2 2026 net product revenue of $18.6 million, a slight increase from $18.1 million in Q2 2025. Cash and cash equivalents stood at $219.1 million as of June 30, 2026.
• The company is evaluating the regulatory path for ZYNLONTA following a pre-sBLA meeting with the FDA, where substantial concerns were raised regarding the LOTIS-5 trial data, particularly concerning benefit-risk and Grade 5 events.
• Enrollment in the LOTIS-7 trial (ZYNLONTA plus glofitamab) is complete, with data submitted for presentation at ASH, supporting the company's belief in its potential as a best-in-class combination.
• A strategic reorganization, including a 17% workforce reduction, is expected to generate approximately $10 million in annualized cost savings.
• Investigator-initiated trials (IITs) for ZYNLONTA in follicular lymphoma (FL) and marginal zone lymphoma (MZL) are advancing, with data submissions planned for ASH.
• The company anticipates growth starting in 2027 and maintains an expected cash runway at least into 2028.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed sentiment. While there's progress in clinical trials and operational updates, significant concerns from the FDA regarding LOTIS-5 trial data and a workforce reduction introduce notable headwinds.

Positives

• Net product revenue increased to $18.6 million in Q2 2026 from $18.1 million in Q2 2025, driven by higher pricing.
• The LOTIS-5 trial met its primary endpoint of progression-free survival (PFS) in combination with rituximab.
• The LOTIS-7 trial, evaluating ZYNLONTA plus glofitamab, has completed enrollment and shows promising data for a potential best-in-class bispecific combination.
• Investigator-initiated trials in MZL and FL are progressing, with data expected for presentation.
• The company has an expected cash runway at least into 2028.
• Total operating expenses decreased by 29% year-over-year in Q2 2026, and adjusted total operating expenses decreased by 22%.

Negatives

• The FDA raised substantial concerns regarding the benefit-risk profile of ZYNLONTA in the LOTIS-5 trial, citing an imbalance in Grade 5 events and marginal treatment benefit.
• The company announced a 17% workforce reduction globally, impacting approximately 17% of its employees.
• License revenues and royalties decreased significantly to $0.6 million in Q2 2026 from $0.8 million in Q2 2025, and $1.4 million for the six months from $6.4 million.
• Cost of product sales increased significantly to $2.3 million in Q2 2026 from $0.8 million in Q2 2025, due to a shift in personnel focus to commercial manufacturing.
• Net loss was $16.6 million in Q2 2026, compared to $56.6 million in Q2 2025. Adjusted net loss was $16.3 million compared to $28.7 million.

Risks

• The FDA's substantial concerns regarding the LOTIS-5 trial data could impede full regulatory approval and the advancement of ZYNLONTA into earlier lines of DLBCL therapy.
• The company is assessing the best regulatory path forward for LOTIS-5 data following FDA feedback, creating uncertainty.
• The strategic reorganization and workforce reduction introduce risks related to operational execution and employee morale.
• The company faces ongoing indebtedness, including significant cash required to service such debt.
• Future revenue growth is dependent on the successful commercialization and regulatory approvals of ZYNLONTA in various settings and combinations.

Future Outlook

The company anticipates growth starting in 2027 and has an expected cash runway at least into 2028. They are working to advance ZYNLONTA into earlier lines of DLBCL therapy and are assessing regulatory pathways for full approval.

Management Comments

• "We are pleased by our second quarter performance, which reflects continued commercial momentum and strong operational discipline through ongoing cost reduction efforts."
• "With these data now in hand, we believe that ZYNLONTA plus glofitamab offers an opportunity to take a leading second-line plus position, in the context of the evolving competitive landscape, solidifying ZYNLONTA as a foundational therapy in DLBCL."
• "Additionally, following the FDA pre-sBLA meeting for the LOTIS-5 trial, we are assessing regulatory approaches to determine the best path forward."
• "We remain confident that ZYNLONTA will continue to play a meaningful role for patients with B-cell malignancies, in the 3L+ DLBCL setting, and through potential compendia inclusion starting in 2027."

Industry Context

StockSavvy.ai notes that the pharmaceutical industry, particularly in oncology, is highly competitive and driven by clinical trial success and regulatory approvals. ADC Therapeutics' focus on ADCs and specific lymphoma indications places it within a dynamic and rapidly evolving therapeutic area. The FDA's scrutiny of LOTIS-5 highlights the rigorous standards for drug approval, especially concerning safety profiles and benefit-risk assessments.

Comparison to Industry Standards

• The LOTIS-5 trial results, while meeting the primary PFS endpoint, faced FDA concerns regarding Grade 5 events and marginal benefit, indicating a high bar for regulatory approval compared to some other oncology trials.
• The LOTIS-7 trial's reported CR rate of 78% (as of Nov 17, 2025) for ZYNLONTA + glofitamab in r/r DLBCL is positioned as potentially best-in-class among bispecific combinations, aiming to compete with CAR-T therapies (e.g., Yescarta with 65% CR, Breyanzi with 66% CR) and other bispecifics (e.g., glofitamab + GEMOX with 59% CR).
• ZYNLONTA's performance in r/r MZL, with a 69% CR rate and 12-month PFS of 92.9% from Phase 2 IIT data, aims to establish a significant role in a less standardized treatment landscape.
• ZYNLONTA + rituximab in r/r FL shows a CR rate of 84% and 24-month PFS of 88.3% from Phase 2 IIT data, positioning it as a strong option against existing treatments like CAR T-cell therapies and bispecific antibodies.

Stakeholder Impact

• Shareholders may be impacted by the negative FDA feedback on LOTIS-5, potentially affecting future revenue projections and stock valuation.
• Employees face uncertainty and potential impact due to the announced 17% workforce reduction.
• Patients and healthcare providers may experience delays or changes in treatment options if regulatory hurdles for ZYNLONTA's expanded use are not overcome.
• Creditors may be concerned by the company's net loss and cash burn, although the runway into 2028 provides some reassurance.

Next Steps

• Assess the best regulatory path forward for LOTIS-5 data following FDA feedback.
• Provide an update on regulatory strategy and timing for LOTIS-5 in the near future.
• Continue to commercialize ZYNLONTA as a monotherapy in the 3L+ DLBCL setting.
• Evaluate a regulatory pathway for the ZYNLONTA plus glofitamab combination and plan to submit for Breakthrough Therapy designation this year.
• Submit LOTIS-7 and MZL data to the FDA for Breakthrough Designation.
• Present LOTIS-5, LOTIS-7, and MZL investigator-initiated trial data at the ASH Annual Meeting.
• Prepare LOTIS-7 trial results for publication and subsequent compendia submission.
• Assess potential regulatory pathways for ZYNLONTA in MZL.

Key Dates

Recommendation

The mixed results, particularly the significant FDA concerns regarding LOTIS-5 and the workforce reduction, introduce considerable uncertainty. While ZYNLONTA shows promise in other trials and indications, the regulatory setback for LOTIS-5 warrants a cautious 'hold' stance until the company clarifies its regulatory strategy and demonstrates a clearer path to market expansion.

Keywords

ZYNLONTA, DLBCL, ADC Therapeutics, LOTIS-5, LOTIS-7, oncology, hematology, clinical trials